Precision for Medicine Partners with SOPHiA GENETICS to Expand Biopharma Services with the SOPHiA DDM™ Platform and its Liquid Biopsy Capabilities
SOPHiA GENETICS (SOPH) and Precision for Medicine have announced a strategic partnership to enhance biomarker discovery and precision medicine services. The collaboration integrates the SOPHiA DDM™ Platform into Precision for Medicine's offerings, providing advanced AI-driven analytics for clinical trials.
The partnership will leverage AI algorithms to analyze multimodal data, including genomic, radiomic, and clinical information, enabling better patient population targeting for clinical trials. A key feature includes the integration of MSK-ACCESS® powered with SOPHiA DDM™, a liquid biopsy test supported by AstraZeneca, which will facilitate retrospective clinical trial data analysis and improve patient stratification.
The collaboration combines Precision for Medicine's wet lab services and clinical trial expertise with SOPHiA GENETICS' AI-based genomic analysis tools, creating a comprehensive solution for biopharma companies to accelerate drug development, particularly in oncology, rare diseases, and genetic disorders.
SOPHiA GENETICS (SOPH) e Precision for Medicine hanno annunciato una partnership strategica per migliorare la scoperta di biomarcatori e i servizi di medicina di precisione. La collaborazione integra la SOPHiA DDM™ Platform nelle offerte di Precision for Medicine, fornendo analisi avanzate basate su intelligenza artificiale per le sperimentazioni cliniche.
La partnership sfrutterà algoritmi di intelligenza artificiale per analizzare dati multimodali, inclusi informazioni genomiche, radiomiche e cliniche, consentendo un migliore targeting della popolazione di pazienti per le sperimentazioni cliniche. Una caratteristica chiave include l'integrazione di MSK-ACCESS® alimentato da SOPHiA DDM™, un test di biopsia liquida supportato da AstraZeneca, che faciliterà l'analisi retrospettiva dei dati delle sperimentazioni cliniche e migliorerà la stratificazione dei pazienti.
La collaborazione combina i servizi di laboratorio umido e l'expertise nelle sperimentazioni cliniche di Precision for Medicine con gli strumenti di analisi genomica basati su intelligenza artificiale di SOPHiA GENETICS, creando una soluzione completa per le aziende biopharma per accelerare lo sviluppo di farmaci, in particolare in oncologia, malattie rare e disturbi genetici.
SOPHiA GENETICS (SOPH) y Precision for Medicine han anunciado una asociación estratégica para mejorar el descubrimiento de biomarcadores y los servicios de medicina de precisión. La colaboración integra la SOPHiA DDM™ Platform en las ofertas de Precision for Medicine, proporcionando análisis avanzados impulsados por inteligencia artificial para ensayos clínicos.
La asociación aprovechará algoritmos de IA para analizar datos multimodales, incluyendo información genómica, radiómica y clínica, permitiendo un mejor enfoque en la población de pacientes para los ensayos clínicos. Una característica clave incluye la integración de MSK-ACCESS® potenciado por SOPHiA DDM™, una prueba de biopsia líquida respaldada por AstraZeneca, que facilitará el análisis retrospectivo de datos de ensayos clínicos y mejorará la estratificación de pacientes.
La colaboración combina los servicios de laboratorio húmedo y la experiencia en ensayos clínicos de Precision for Medicine con las herramientas de análisis genómico basadas en IA de SOPHiA GENETICS, creando una solución integral para las empresas biopharma para acelerar el desarrollo de fármacos, particularmente en oncología, enfermedades raras y trastornos genéticos.
SOPHiA GENETICS (SOPH)와 Precision for Medicine은 바이오마커 발견 및 정밀 의학 서비스를 향상시키기 위한 전략적 파트너십을 발표했습니다. 이 협력은 SOPHiA DDM™ Platform을 Precision for Medicine의 서비스에 통합하여 임상 시험을 위한 고급 AI 기반 분석을 제공합니다.
파트너십은 유전체, 방사선 및 임상 정보를 포함한 다중 모드 데이터를 분석하기 위해 AI 알고리즘을 활용하여 임상 시험을 위한 환자 집단 타겟팅을 개선합니다. 주요 기능 중 하나는 AstraZeneca의 지원을 받는 액체 생검 테스트인 MSK-ACCESS®와 SOPHiA DDM™의 통합으로, 이는 임상 시험 데이터 분석을 용이하게 하고 환자 분류를 개선합니다.
이 협력은 Precision for Medicine의 습식 실험실 서비스와 임상 시험 전문성을 SOPHiA GENETICS의 AI 기반 유전체 분석 도구와 결합하여, 특히 종양학, 희귀 질환 및 유전적 장애 분야에서 의약품 개발을 가속화하는 포괄적인 솔루션을 제공합니다.
SOPHiA GENETICS (SOPH) et Precision for Medicine ont annoncé un partenariat stratégique pour améliorer la découverte de biomarqueurs et les services de médecine de précision. La collaboration intègre la SOPHiA DDM™ Platform dans les offres de Precision for Medicine, fournissant des analyses avancées pilotées par l'intelligence artificielle pour les essais cliniques.
Le partenariat exploitera des algorithmes d'IA pour analyser des données multimodales, y compris des informations génomiques, radiomiques et cliniques, permettant ainsi un meilleur ciblage des populations de patients pour les essais cliniques. Une caractéristique clé est l'intégration de MSK-ACCESS®, alimenté par SOPHiA DDM™, un test de biopsie liquide soutenu par AstraZeneca, qui facilitera l'analyse rétrospective des données d'essais cliniques et améliorera la stratification des patients.
La collaboration combine les services de laboratoire humide et l'expertise en essais cliniques de Precision for Medicine avec les outils d'analyse génomique basés sur l'IA de SOPHiA GENETICS, créant une solution complète pour les entreprises biopharmaceutiques afin d'accélérer le développement de médicaments, en particulier en oncologie, dans les maladies rares et les troubles génétiques.
SOPHiA GENETICS (SOPH) und Precision for Medicine haben eine strategische Partnerschaft angekündigt, um die Entdeckung von Biomarkern und die Dienstleistungen der Präzisionsmedizin zu verbessern. Die Zusammenarbeit integriert die SOPHiA DDM™ Platform in das Angebot von Precision for Medicine und bietet fortschrittliche, KI-gesteuerte Analysen für klinische Studien.
Die Partnerschaft wird KI-Algorithmen nutzen, um multimodale Daten zu analysieren, einschließlich genomischer, radiomischer und klinischer Informationen, um eine bessere Zielgruppenansprache für klinische Studien zu ermöglichen. Ein zentrales Merkmal ist die Integration von MSK-ACCESS®, das mit SOPHiA DDM™ betrieben wird, einem von AstraZeneca unterstützten Liquid-Biopsietest, der die retrospektive Analyse von klinischen Studiendaten erleichtert und die Patientenschichtung verbessert.
Die Zusammenarbeit kombiniert die Dienstleistungen von Precision for Medicine im Bereich der Wet-Lab-Services und die Expertise in klinischen Studien mit den KI-basierten genomischen Analysetools von SOPHiA GENETICS und schafft eine umfassende Lösung für Biopharma-Unternehmen, um die Arzneimittelentwicklung, insbesondere in der Onkologie, bei seltenen Krankheiten und genetischen Störungen, zu beschleunigen.
- Integration of advanced AI-driven analytics enhances clinical trial capabilities
- Partnership expands market reach through MSK-ACCESS® liquid biopsy test deployment
- Creates comprehensive end-to-end solution for biopharma companies
- Potential to reduce trial costs and accelerate therapy development
- None.
Insights
This strategic partnership represents a significant commercial development for SOPHiA GENETICS, extending their market reach by embedding their DDM™ Platform within Precision for Medicine's biopharma services ecosystem. The arrangement creates a multi-faceted value proposition:
First, it establishes a new distribution channel for SOPHiA's technology through Precision's established biopharma client relationships, potentially accelerating platform adoption without requiring the same level of direct sales investment. Second, it packages SOPHiA's advanced analytics capabilities with Precision's wet lab services to create an end-to-end solution - addressing the common implementation barrier where biopharma companies must otherwise integrate multiple vendors.
The inclusion of MSK-ACCESS® powered with SOPHiA DDM™ (already deployed globally with AstraZeneca's support) adds particular strategic value. This liquid biopsy capability enhances the partnership's marketability to oncology-focused clients, where precision medicine approaches are advancing rapidly. The AstraZeneca connection also provides implicit blue-chip validation for SOPHiA's technology.
While financial terms aren't disclosed, B2B partnerships of this nature typically generate revenue through technology licensing, per-sample fees, or revenue-sharing arrangements. For SOPHiA GENETICS, whose market cap stands at only
This partnership addresses several critical technical bottlenecks in precision medicine development. SOPHiA's AI-driven multimodal data analysis capabilities - spanning genomic, radiomic, and clinical information - enable more sophisticated biomarker discovery and patient stratification than traditional single-dimension analytics. For biopharma companies, this translates to potentially more efficient clinical trials through improved patient selection and enhanced understanding of response patterns.
The liquid biopsy component is particularly valuable from a technical standpoint. Traditional tissue biopsies present significant limitations in clinical trials: they're invasive, difficult to obtain serially, and may not capture tumor heterogeneity. Incorporating MSK-ACCESS® powered with SOPHiA DDM™ provides a minimally invasive alternative for monitoring genetic changes throughout treatment, enabling more dynamic trial designs and potentially more nuanced efficacy assessments.
The partnership's emphasis on retrospective clinical trial data analysis also addresses a significant unmet need in precision medicine development. By enabling analysis of historical treatment responses in relation to specific genomic signatures, biopharma companies can refine development strategies before committing substantial resources to prospective trials. This capability may prove especially valuable in oncology and rare diseases, where SOPHiA has established expertise.
The integrated approach eliminates technological friction between separate bioinformatics and laboratory service providers, potentially reducing implementation timelines and technical compatibility issues that frequently delay precision medicine programs. For SOPHiA, this partnership extends their technical capabilities into new workflows without requiring development of in-house laboratory infrastructure.
The partnership integrates advanced AI-driven analytics and clinical trial solutions, empowering biopharma companies to accelerate drug development and deliver targeted therapies faster.
Through this partnership, Precision for Medicine will leverage the SOPHiA DDMTM Platform's advanced AI-driven algorithms to analyze complex multimodal data, including genomic, radiomic, and clinical data. This capability will allow biopharma companies to identify and target the most appropriate patient populations for clinical trials, accelerating biomarker discovery and improve diagnostic capabilities. This is crucial for precision medicine efforts in oncology, rare diseases, and genetic disorders, where understanding the specific genomic characteristics of each patient may enable more targeted therapies.
Additionally, MSK-ACCESS® powered with SOPHiA DDMTM, an innovative liquid biopsy test being deployed globally with the support of AstraZeneca, will be made available as a Precision for Medicine service for biopharma clients. Data generated by this genomically rich, globally deployed test will enable retrospective clinical trial data analysis and improve patient stratification. This capability allows biopharma companies to refine and optimize their clinical trial designs by better understanding how patients responded to previous treatments. This evidence-based approach can help companies fine-tune their drug development strategies, improve patient recruitment for trials, and gain deeper insights into the efficacy of therapies in real-world settings.
"We're thrilled to partner with SOPHiA GENETICS to integrate the SOPHiA DDMTM Platform and integrate MSK-ACCESS® powered with SOPHiA DDMTM into our offering, providing biopharma companies with the tools to accurately identify the right patient populations for enrollment into clinical trials," said Darren Davis, PhD, Senior Vice President Precision for Medicine. "By leveraging AI-powered algorithms and machine learning, we can pinpoint biomarkers and genomic signatures that enable more efficient, targeted trials and improve therapeutic efficacy. This ultimately helps speed up patient enrollment, reduce trial costs, and bring therapies to market faster."
Through this partnership, Precision for Medicine will provide wet lab services, alongside data analysis and clinical trial support, offering biopharma companies expanded capabilities under one umbrella. This integrated approach allows clients to rely on a single solution provider, with Precision for Medicine and SOPHiA GENETICS working together to deliver seamless end-to-end support for their drug development programs.
"Our collaboration with Precision for Medicine enables us to expand the reach and impact of our SOPHiA DDMTM Platform and deliver real-time actionable insights across the clinical trial continuum," said Ross Muken, President at SOPHiA GENETICS. "By combining our AI-powered Platform with Precision for Medicine's cutting-edge clinical trial solutions, we can deliver comprehensive, data-driven capabilities to biopharma companies, accelerating the path to market for precision therapies."
Precision for Medicine's established clinical trial expertise, including biomarker testing and wet lab services, combined with SOPHiA GENETICS' AI-based genomic analysis tools, creates a powerful comprehensive solution for biopharma companies. Biopharma clients can now accelerate drug development with a seamless solution for data analysis and clinical support, enabling more efficient progression from preclinical research to market readiness. This collaboration provides a competitive edge, allowing clients to bring innovative therapies to patients faster and improve market positioning in the highly competitive biopharma landscape.
This exciting partnership is a key driver of innovation in precision medicine, providing biopharma companies with tools to better understand patient genomic makeup and develop personalized treatments for complex diseases. The collaboration enables biopharma companies to tailor treatments based on specific genomic profiles, with the potential to enhance outcomes, patient satisfaction, and the market value of their products. This patient-centric approach aims to fuel breakthroughs in oncology, rare diseases, and other high-unmet-medical areas.
About Precision for Medicine
Precision for Medicine is the first biomarker-driven clinical research and development services organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments more precisely and effectively. Precision applies a transformational approach to clinical research that integrates clinical trial design and execution with deep scientific knowledge, laboratory expertise and advanced data intelligence. This convergence is driving faster clinical development and approval. Precision for Medicine is part of Precision Medicine Group, with 3,400 people in 40 locations globally across
Contact
Brad Epstein
Brad.epstein@precisionformedicine.com
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to unlock insights to deliver world-class care to patients across the globe. It is the creator of SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact support@sophiagenetics.com to obtain the appropriate product information for your country of residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management's beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the
Media Contact:
Kelly Katapodis
View original content to download multimedia:https://www.prnewswire.com/news-releases/precision-for-medicine-partners-with-sophia-genetics-to-expand-biopharma-services-with-the-sophia-ddm-platform-and-its-liquid-biopsy-capabilities-302422644.html
SOURCE Precision for Medicine
FAQ
What capabilities does the SOPHiA GENETICS (SOPH) and Precision for Medicine partnership offer to biopharma companies?
How will the MSK-ACCESS® liquid biopsy test benefit clinical trials under this partnership?
What specific data types can the SOPHiA DDM™ Platform analyze in clinical trials?
Which therapeutic areas will benefit from the SOPH partnership with Precision for Medicine?
